|Bid||12.50 x 1000|
|Ask||12.68 x 1100|
|Day's Range||12.00 - 12.75|
|52 Week Range||10.06 - 14.32|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
went public on Thursday in a deal that highlights a large market that has drawn little venture investment until recently. The company, a spinoff of SoftBank-backed Roivant Sciences, is developing a drug to treat an overactive bladder, a condition that affects millions of Americans and is a serious public-health burden, according to a 2016 study published in the journal Current Bladder Dysfunction Reports. In recent years the number of venture rounds completed in urology each year has typically been in the single digits, according to Dow Jones VentureSource.
BASEL, Switzerland and IRVINE, Calif. , Sept. 26, 2018 /PRNewswire/ -- Urovant Sciences Ltd. (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing therapies for urologic conditions, ...
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . Viomi Technology Co., Ltd ( VIOT ) will issue 11.4 million shares between $9 and $11 Tuesday on the Nasdaq. Headquartered ...